 | Up a level |
Martel, Samuel, Bruzzone, Marco 
ORCID: 0000-0002-8821-4542, Ceppi, Marcello ORCID: 0000-0002-8177-8003, Maurer, Christian, Ponde, Noam Falbel, Ferreira, Arlindo R., Viglietti, Giulia, Del Mastro, Lucia ORCID: 0000-0002-9546-5841, Prady, Catherine, de Azambuja, Evandro ORCID: 0000-0001-9501-4509 and Lambertini, Matteo ORCID: 0000-0003-1797-5296
(2018).
Risk of adverse events with the addition of targeted agents to endocrine therapy in patients with hormone receptor-positive metastatic breast cancer: A systematic review and meta-analysis.
Cancer Treat. Rev., 62.
S. 123 - 133.
OXFORD:
ELSEVIER SCI LTD.
ISSN 1532-1967
Poggio, Francesca, Bruzzone, Marco, Ceppi, Marcello, Conte, Benedetta, Martel, Samuel, Maurer, Christian, Tagliamento, Marco ORCID: 0000-0001-7461-023X, Viglietti, Giulia, Del Mastro, Lucia ORCID: 0000-0002-9546-5841, De Azambuja, Evandro and Lambertini, Matteo
(2018).
PARP inhibitors (PARPi) for the treatment of BRCA-mutated HER2negative (HER2-) metastatic breast cancer (MBC) patients: A systematic review and meta-analysis.
J. Clin. Oncol., 36 (15).
ALEXANDRIA:
AMER SOC CLINICAL ONCOLOGY.
ISSN 1527-7755
Poggio, Francesca ORCID: 0000-0002-4518-2827, Bruzzone, Marco ORCID: 0000-0002-8821-4542, Ceppi, Marcello ORCID: 0000-0002-8177-8003, Conte, Benedetta, Martel, Samuel, Maurer, Christian, Tagliamento, Marco ORCID: 0000-0001-7461-023X, Viglietti, Giulia, Del Mastro, Lucia ORCID: 0000-0002-9546-5841, de Azambuja, Evandro ORCID: 0000-0001-9501-4509 and Lambertini, Matteo ORCID: 0000-0003-1797-5296
(2018).
Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis.
ESMO Open, 3 (4).
LONDON:
BMJ PUBLISHING GROUP.
ISSN 2059-7029